 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...99100101102103104105106107108109...123124» |
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
In combinations, we start with lenvatinib 10 mg po daily (Twitter) - Jul 7, 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Any particular dose of Lenvatinib you prefer in such cases ? Bcos the recommended dose ranges from 12mg in HCC to 24 mg in Thryoid Ca . (Twitter) - Jul 7, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. (Pubmed Central) - Jul 7, 2020
These studies bring forward novel drug combinations to complement lenvatinib for treating anaplastic thyroid cancer. Such combinations may possibly reduce the chances of lenvatinib resistance in thyroid cancer patients.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Agree. Have found pi3k and mek nearly impossible to give together. Both tough class of drugs. I would imagine giving fgfr inh w lenvatinib would also be tough in Indian population but could certainly be attempted. I wish we could figure out the best regimen in vitro somehow? (Twitter) - Jul 7, 2020
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Bilateral Pneumothoraces Secondary to Lenvatinib (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_6575;
The pneumothorax may resolve with drainage and discontinuation of the TKI. While rare, it is important to recognize tumor necrosis secondary to multi-site targeting TKI can be a cause of recurrent and persistent pneumothoraces.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
We’re on pembro. How do we get Eisai to help out with a compassionate use lenvatinib addition? (Twitter) - Jul 6, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial - The Lancet Oncology https://t.co/d4C1piiTcJ (Twitter) - Jul 6, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial https://t.co/k2lpfjTyES (Twitter) - Jul 6, 2020
- || lenvatinib / Generic mfg.
Clinical, Journal: Second-line lenvatinib in patients with recurrent endometrial cancer. (Pubmed Central) - Jul 3, 2020
While rare, it is important to recognize tumor necrosis secondary to multi-site targeting TKI can be a cause of recurrent and persistent pneumothoraces. Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
I am tx’ng a 30ish man exactly in that situation. CPS 10, TMB moderate. T4b, N3 (by CT PET). On FOLFOX. Could we add IO? Lenvatinib + IO or wait for failure then go 2nd line? (Twitter) - Jul 2, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov) - Jul 1, 2020
P2, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies. N=180 --> 600 | Trial completion date: Apr 2022 --> Feb 2024 | Trial primary completion date: Apr 2022 --> Feb 2024
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
ما Lenvatinib را با ارزانترین قیمت می فروشیم. اگر علاقه مند هستید از طریق Wechat یا WhatsApp با من تماس بگیرید: +8801409411722. (Twitter) - Jul 1, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Prediction: response will be ‘but lenvatinib/IO’ (Twitter) - Jul 1, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: This week @RuthHe12 and @marshalj23 highlighted "Lenvatinib plus pembrolizumab in patients with advanced #GastricCancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial" as an important study @TheLancetOncol. https://t.co/8S9cA1kZDf (Twitter) - Jun 30, 2020
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Lenvatinib and pembro had a 69% response rate (n=29) in gastric cancer! VEGF/IO randomised results have been inconsistent in renal cancer. Results for the combination of pembrol & lenvatinib should be good and are awaited. @Uromigos @motzermd @DrChoueiri (Twitter) - Jun 30, 2020
- | Trial completion date, Trial primary completion date: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Jun 29, 2020
P1, N=40, Recruiting, Sponsor: OHSU Knight Cancer Institute
N=180 --> 600 | Trial completion date: Apr 2022 --> Feb 2024 | Trial primary completion date: Apr 2022 --> Feb 2024 Trial completion date: Feb 2021 --> Feb 2025 | Trial primary completion date: Feb 2021 --> Feb 2022
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] COOPERATION BETWEEN DISTINCT CANCER DRIVER GENES UNDERLIES INTER-TUMOR HETEROGENEITY IN HEPATOCELLULAR CARCINOMA () - Jun 29, 2020 - Abstract #ILCA2020ILCA_30;
Introduction: Several therapies are now approved for the treatment of advanced hepatocellular carcinoma patients, including the multikinase inhibitors sorafenib, regorafenib, lenvatinib, and cabozantinib, the VEGFR2 antagonist ramucirumab, and the immunotherapies pembrolizumab and nivolumab, the latter alone or in combination with ipilimumab... Altogether, this novel collection of murine HCC models and corresponding cell lines establishes the role of driver genes in diverse contexts and enables mechanistic and translational studies.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] IMMUNE-REMODELING EFFECTS OF LENVATINIB PLUS ANTI-PD1 IN A MURINE MODEL OF HEPATOCELLULAR CARCINOMA () - Jun 29, 2020 - Abstract #ILCA2020ILCA_22;
Lenvatinib exerted an immunomodulatory effect characterized by a reduction of Treg infiltrate and inhibition of immunosuppressive pathways, which in combination with anti-PD1 favored an activated immunological profile and faster response to treatment. The obtained gene signature could be a tool for identifying ideal candidate patients to combination therapy.
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] RAMUCIRUMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ELEVATED ALPHA FETOPROTEIN FOLLOWING A NON-SORAFENIB BASED SYSTEMIC THERAPY: INTERIM RESULTS FROM AN EXPANSION COHORT OF THE PHASE 3 REACH-2 STUDY () - Jun 29, 2020 - Abstract #ILCA2020ILCA_9;
P3
The most common prior systemic therapies were lenvatinib (n=8), monotherapy PD-1 or PD-L1 inhibitor (n=9), PD-1 inhibitor plus lenvatinib (n=3), and atezolizumab plus bevacizumab (n=3). At this interim analysis, the safety and efficacy profile of ramucirumab following a non-sorafenib based systemic therapy was consistent with that observed in patients who received prior sorafenib in the ITT population of REACH-2.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Emerging agents and regimens for hepatocellular carcinoma. (Pubmed Central) - Jun 28, 2020
The combination of an anti-PD-1 antibody and an anti-angiogenesis agent has shown more potent anti-tumor effects in early phase clinical trials and is now the hotspot in clinical studies. Furthermore, these agents are investigated in combination treatment with surgery or other loco-regional therapies in patients with early or intermediate-stage HCC.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Speaks to likely synergy of immune checkpoint and VEGF blockade also seen with rego + nivo and lenvatinib + pembro. (Twitter) - Jun 27, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. (Pubmed Central) - Jun 27, 2020
Pharmacist interventions in collaboration with medical oncologists improved lenvatinib therapy. Interventions for outpatients were conducted not only in outpatient clinics but also by telephone follow-up, clarifying the importance of continuous management for patients at risk of adverse reactions and misuse of oral medicine.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, HEOR: Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. (Pubmed Central) - Jun 26, 2020
Interventions for outpatients were conducted not only in outpatient clinics but also by telephone follow-up, clarifying the importance of continuous management for patients at risk of adverse reactions and misuse of oral medicine. Lenvatinib was cost-effective compared with sorafenib for the first-line treatment of uHCC in Japan.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, P3 data: Anecdotally, teleologically, and pre-clinically it makes sense, and now with even more small phase 2’s in various tumour types. A phase 3 lenvatinib + pembro vs pembro in high tmb and lenvatinib/pembro vs INV choice in low tmb would be a helpful study :) (or equivalent drugs) (Twitter) - Jun 25, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. (Pubmed Central) - Jun 25, 2020
Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue. The occurrence of carnitine insufficiency may be a common cause of fatigue during the treatment.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jun 25, 2020
P2, N=17, Recruiting, Sponsor: Emory University
The occurrence of carnitine insufficiency may be a common cause of fatigue during the treatment. Not yet recruiting --> Recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Pan tumor: E7080-G000-231: A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (clinicaltrials.gov) - Jun 25, 2020
P2, N=150, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial - The Lancet Oncology https://t.co/TI2mEzhuE6 (Twitter) - Jun 24, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
داروی لنواتینیب (انگلیسی: Lenvatinib) با نام تجاری لِنویما یک داروی ضد سرطان است که جهت درمانِ برخی از انواع سرطان تیروئید و همچنین چند سرطان دیگر بهکار میرود #HPV #humanpapillomavirus (#HPV). @merck (Twitter) - Jun 24, 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: KEYMAKER-U02 Substudy 02A: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (clinicaltrials.gov) - Jun 23, 2020
P1/2, N=200, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov) - Jun 23, 2020
P1/2, N=135, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Pembro and lenvatinib in gastric cancer. Great work from a leader in the field. Worth the read. @KoheiShitara @TheLancetOncol (Twitter) - Jun 23, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
It is our pleasure to report the results from Phase 2 of lenvatinib plus pembrolizumab for gastric cancer https://t.co/NltmhBXm9u (Twitter) - Jun 23, 2020
- ||| sitravatinib (MGCD516) / Mirati, Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
I'd be more inclined to consider 1L platinum doublet with or without pembro but in 2L find a trial of a PD-1 + VEGF TKI like lenvatinib or sitravatinib (Twitter) - Jun 23, 2020
- | Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Jun 23, 2020
P1, N=488, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. (clinicaltrials.gov) - Jun 22, 2020
P=N/A, N=170, Not yet recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
- | Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) (clinicaltrials.gov) - Jun 22, 2020
P=N/A, N=20, Not yet recruiting, Sponsor: RenJi Hospital
- | Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Dulect2020-2: Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jun 22, 2020
P=N/A, N=20, Not yet recruiting, Sponsor: Shanghai First Maternity and Infant Hospital
- |||| AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Combination therapy, Metastases: Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=53, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- || Kaitanni (cadonilimab) / Akesobio
New P1/2 trial, Combination therapy, Metastases: AK104-206: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=30, Recruiting, Sponsor: Akeso
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers (clinicaltrials.gov) - Jun 22, 2020
P2, N=44, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2023 Initiation date: Feb 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2022
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2264;
The appearance of fatigue, the typical symptom of PAI, could be multifactorial in these pts due also to the direct effect of TKIs treatment. Thus, in these cases is very difficult to recognize the cause of fatigue and to decide the appropriate treatment (cortisone acetate replacement therapy vs TKIs dose reduction).
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Dramatic Clinical Response to Lenvatinib in a Pediatric Patient with Advanced Metastatic Papillary Thyroid Carcinoma () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2192;
On lenvatinib treatment, our patient showed significant clinical improvement, arrest of disease progression, and stable disease on imaging studies. This case shows that lenvatinib may be a beneficial option for children with advanced PTC not amenable to surgery/RAI treatment and may be used as a bridge to these first-line therapies.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Combined Treatment with Laser Ablation and Tyrosin Kinase Inhibitors. a Novel Multimodality Approach to Locally Advanced Thyroid Cancer? () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2117;
In May 2017, due to initial regrowth of the tumor mass, the patient started therapy with Lenvatinib, at 10-24 mg/day...Discussion. These preliminary results suggest that locally-advanced unresectable and radioiodine-refractory thyroid tumors can be managed with preliminary LTA mass debulking, for rapid control of local disease, followed by long-term TKI treatment.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Tafinlar (dabrafenib) / Novartis
[VIRTUAL] Complex Thyroid Cancer with Several Recurrences and Metastases () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2116;
This patient demonstrated excellent response to I-131 therapy with lenvatinib pretreatment.A number of formal studies of various TKIs for thyroid cancer re-differentiation are currently underway. (cite Brown SR, Hall A, et al BMC cancer 2019; and also cite the CIII trial with cabozatanib)Conclusion This case represents the emerging paradigm for the ability of TKI therapy to redifferentiate advanced thyroid cancer and allow for re-treatment with I-131 targeted therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] The Short-Term Effect of Multiple Kinase Inhibitor (Lenvatinib) on Spermatogenesis in Mice () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1768;
We conclude that 6 weeks of Lenvatinib treatment had minimal effect if any on mouse spermatogenesis. The long-term treatment effect of Lenvatinib on spermatogenesis remains to be determined.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. (Pubmed Central) - Jun 20, 2020
The long-term treatment effect of Lenvatinib on spermatogenesis remains to be determined. Advanced portal hypertension was associated with the therapeutic efficacy of lenvatinib in controlling the progression of HCC in patients with poor liver function.
- || Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. (Pubmed Central) - Jun 19, 2020
Following a decade of negative Phase III trials since the approval of sorafenib, more recently several drugs have proven efficacy both in first line versus sorafenib (lenvatinib) or in second line versus placebo (regorafenib, cabozantinib, ramucirumab)...For the first time in the history of systemic treatments for HCC, a predictive factor of efficacy was identified. In this review, we also discuss the potential clinical development of systemic treatments in HCC, focusing on combination therapies with immunotherapy (following the recent results of the combination of atezolizumab and bevacizumab in the IMbrave 150 clinical trial) and treatment sequences as a way to maximize survival benefit.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. (Pubmed Central) - Jun 19, 2020
This study demonstrates that RDI is an important predictive factor for longer PFS during lenvatinib treatment. In this hypothesis-generating exploratory analysis, we report that a CAF-signature associated with adverse events and RDI could predict PFS, which might contribute to improved management of lenvatinib treatment in HCC patients.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
2/2 You may try a TKI off level eg Lenvatinib during the period when anti myeloma drugs are off in a sequential manner (day 21-28). If he achieves a good response go ahead with an allogeneic transplant. May be antiBCMA CART... (Twitter) - Jun 19, 2020